Cardiovascular Risk and the Use of Biologic Agents in Rheumatoid Arthritis

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Although patients with rheumatoid arthritis (RA) are recognized to be disproportionately impacted by cardiovascular disease (CVD), effective approaches of primary and secondary CVD prevention have not been well defined in this population. Given their robust disease-modifying potential and effects on both pro-inflammatory and pro-atherogenic pathways, there has been substantial speculation that biologic treatments may serve as a means of providing highly effective RA disease control while simultaneously reducing CVD risk in this high risk group. In this review, we examine available evidence relevant to the associations of approved biologic treatments with CVD outcomes in the context of RA.

Original languageEnglish (US)
Article number459
JournalCurrent rheumatology reports
Issue number11
StatePublished - Nov 2014


  • Atherosclerosis
  • Biologic
  • Cardiovascular disease
  • Myocardial infarction
  • Rheumatoid arthritis
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Cardiovascular Risk and the Use of Biologic Agents in Rheumatoid Arthritis'. Together they form a unique fingerprint.

Cite this